Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
Title:
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
Author:
Balañá, C. Vaz, M. A. Lopez, D. Peñas, R. de la García-Bueno, J. M. Molina-Garrido, M. J. Sepúlveda, J. M. Cano, J. M. Bugés, C. Sanz, S. M. Arranz, J. L. Perez-Segura, P. Rodriguez, A. Martin, J. M. Benavides, M. Gil, M.